Pulmonology 1
Pulmonology 2
Pulmonology 3
Pulmonology 4
Pulmonology 5
100

Trimester of pregnancy with most frequent asthma exacerbations

Second trimester

100

Possible complication during air travel in asthma or COPD

Pneumothorax

100

Physical manifestation of CSA due to heart failure

Cheyne-Stokes breathing

100

High-prevalence condition in young patients with DPLD

Connective tissue disease

100

Common drug cause of CSA

Opioids

200

Imaging for evaluation of solid lung nodule >8 mm

CT and PET

200

Pleural fluid LDH level in exudative pleural effusion

>2/3 upper limit of normal for serum LDH

200

Most common causes of pleural effusion

Heart failure, pneumonia, malignancy

200

Antibiotic class for severe COPD with frequent exacerbations

Macrolide

200

Conditions warranting in-lab polysomnography

Cardiopulmonary or neuromuscular disease

300

Diagnostic tests for allergic bronchopulmonary aspergillosis

Aspergillus-specific IgE and IgG; total IgE; Aspergillus antigen skin test; blood eosinophil

300

Drug treatments for high-altitude pulmonary edema

Nifedipine, PDE-5 inhibitor

300

Add-on therapy to short-acting bronchodilators in COPD

LABA and/or LAMA

300

Asthma monotherapy associated with increased mortality

LABA

300

Empiric antibiotic class for bronchiectasis exacerbation

Fluoroquinolone

400

Characteristics of idiopathic NSIP compared with IPF

Typically affects younger population, has more favorable prognosis

400

Treatment for CTEPH

Pulmonary thromboendarterectomy and anticoagulation

400

Most common causes of lymphocyte-predominant pleural effusion

TB, cancer

400

Role of sputum culture in COPD exacerbation

None

400

Symptoms and history suggestive of mesothelioma

Asbestos exposure, chest pain, night sweats, recurrent pleural effusion

500

Diagnosis suggested by environmental exposure, fever, fatigue, cough

Hypersensitivity pneumonitis

500

Anterior mediastinal mass entities

Thymoma, teratoma, lymphoma, thyroid

500

Noninvasive tool to quantify eosinophilic airway inflammation

Fractional exhaled nitric oxide test

500

First-line therapy for PAH if tolerated

Endothelin-1 receptor antagonist plus PDE-5 inhibitor

500

OHS defining parameter

Daytime hypercapnia

M
e
n
u